# ASP-1929 Photoimmunotherapy (PIT) Study in Recurrent Head/Neck Cancer for Patients Who Have Failed at Least Two Lines of Therapy

Source: https://onco.cc/trials/nct03769506/  
OnCo record `nct03769506` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of ASP-1929 Photoimmunotherapy in head and neck squamous cell carcinoma, run by Rakuten Medical, Inc., active and no longer recruiting.

## Summary

ASP-1929 Photoimmunotherapy (PIT) Study in Recurrent Head/Neck Cancer for Patients Who Have Failed at Least Two Lines of Therapy is a phase 3 interventional study registered as NCT03769506 by Rakuten Medical, Inc., with 135 participants enrolled, started 2019-05-09 and due to reach its primary completion in 2025-12. Interventions recorded: ASP-1929 Photoimmunotherapy and Physician's Choice SOC.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT03769506
- Phase: 3
- Setting: A Phase 3, Randomized, Double-Arm, Open-Label, Controlled Trial of ASP-1929 Photoimmunotherapy Versus Physician's Choice Standard of Care for the Treatment of Locoregional, Recurrent Head and Neck Squamous Cell Carcinoma in Patients Who Have Failed or Progressed On or After at Least Two Lines of Therapy, of Which at Least One Line Must Be Systemic Therapy
- Sponsor: Rakuten Medical, Inc.
- Enrolled: 135

## Sources

- ClinicalTrials.gov NCT03769506: https://clinicaltrials.gov/study/NCT03769506

## Connected records

- cancers: [Head and neck squamous cell carcinoma](https://onco.cc/cancers/head-and-neck/)
- companies: [Rakuten Medical](https://onco.cc/companies/rakuten-medical/)

---
JSON: https://onco.cc/api/v1/entities/nct03769506.json